Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969. 

The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.  

The NLRP3 inflammasome is a critical component of the innate immune system but its aberrant activation is recognised as a driver of neuroinflammation. This contributes to the pathology of multiple neurodegenerative diseases, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). 

Preliminary data has demonstrated ISM8969’s efficacy, favourable safety profile and marked anti-inflammatory activity in disease models. 

Insilico will lead the initial clinical development, including IND submission and execution of the Phase I clinical trial for the Parkinson’s disease indication. Hygtia Therapeutics will assume leadership of subsequent global clinical studies, regulatory submissions, and commercialisation activities. 

“Targeting neuroinflammation via NLRP3 represents a scientifically sound and high potential approach to treating neurodegenerative and age-related diseases,” said Ren Feng, Co-CEO and Chief Scientific Officer of Insilico Medicine.  

“However, developing a safe molecule with good blood-brain barrier penetration remains a formidable obstacle for drug developers. Through our generative AI platform, we have designed a molecule specifically engineered to overcome this barrier.” 

“We are delighted to enter this strategic collaboration with Insilico Medicine, which marks a pivotal step in our global strategy,” Hygtia Therapeutics said in a press release. 

“This partnership aligns with our strategy to expand our innovative neuroscience pipeline through high quality assets. 

“This BBB-penetrating NLRP3 inhibitor directly reflects our commitment to creating globally competitive innovations. We will advance its development through a collaborative alliance, uniting our strengths to deliver better therapeutic solutions worldwide.” 

 

Bruno Quinney, Content Team, DDW